Allergy medication safe for kidneys is an important consideration for the estimated 3 million people in the UK living with chronic kidney disease (CKD). Reduced kidney function affects how the body processes and clears drugs, meaning some common allergy remedies — including certain antihistamines, decongestants, and NSAIDs — can accumulate, worsen kidney function, or interact with CKD medications. Understanding which treatments are appropriate, which require dose adjustment, and which should be avoided altogether is essential for managing allergies safely when kidney health is already compromised.

How Kidney Function Affects Allergy Medication Safety

Reduced kidney function slows drug clearance, causing medications to accumulate to higher levels; allergy drugs vary in their degree of renal excretion, so dose adjustments are drug-specific and must be checked in the BNF or SmPC.

The kidneys play a central role in filtering waste products and medications from the bloodstream. When kidney function is reduced, the body's ability to clear drugs slows considerably, meaning medications can accumulate to higher-than-intended levels and increase the risk of side effects or toxicity.

Experiencing these side effects? Our pharmacists can help you navigate them →

Kidney function is measured using estimated glomerular filtration rate (eGFR). Reduced kidney function is classified as chronic kidney disease (CKD) when eGFR is persistently below 60 mL/min/1.73m², or when eGFR is 60–89 mL/min/1.73m² alongside other markers of kidney damage — such as elevated urine albumin-to-creatinine ratio (ACR) — persisting for three months or more, as defined by NICE NG203. An eGFR of 60–89 mL/min/1.73m² alone, without additional evidence of kidney damage, does not constitute CKD.

Allergy medications are processed through a combination of hepatic (liver) metabolism and renal (kidney) excretion. The proportion eliminated by the kidneys varies significantly between individual drugs, and renal dose adjustment thresholds are therefore drug-specific — they should always be checked in the current BNF or Summary of Product Characteristics (SmPC) rather than applied as a single blanket threshold.

For patients with moderate to severe CKD, or those on dialysis, careful consideration of drug choice and dosing is essential. It is also worth noting that certain allergy medications — particularly decongestants — can raise blood pressure and reduce blood flow to the kidneys, both of which are areas of particular concern in patients with CKD. First-generation antihistamines carry separate concerns around sedation and anticholinergic effects, which may be more pronounced when drug clearance is reduced.

Antihistamines and Kidney Disease: What the Evidence Shows

Second-generation antihistamines are preferred in CKD, but renal profiles differ: cetirizine requires dose reduction in moderate-to-severe impairment, while loratadine and fexofenadine have more favourable profiles, though fexofenadine exposure increases with renal impairment.

Antihistamines are the most commonly used allergy medications and are broadly divided into two generations. First-generation antihistamines — such as chlorphenamine (Piriton) and promethazine — cross the blood-brain barrier and are associated with sedation, confusion, and anticholinergic effects (dry mouth, urinary retention, constipation). These effects can be more pronounced in patients with CKD due to reduced drug clearance, making them generally less suitable for this group.

Not sure if this is normal? Chat with one of our pharmacists →

Second-generation antihistamines — including cetirizine, loratadine, fexofenadine, and desloratadine — are preferred for most patients because they cause less sedation and have a more predictable pharmacokinetic profile. However, their renal excretion profiles differ, and the appropriate choice depends on the individual's kidney function, comorbidities, and other medications:

• Cetirizine is predominantly renally excreted and can accumulate in patients with reduced kidney function. The BNF and UK SmPC advise dose reduction in moderate-to-severe renal impairment (typically 5 mg once daily when eGFR is below 30–50 mL/min/1.73m², depending on the product). Cetirizine is generally not recommended or is contraindicated in end-stage renal disease; always confirm the current guidance in the relevant SmPC.

• Loratadine is primarily metabolised by the liver, which means renal dose adjustment is not routinely required in mild-to-moderate CKD, though caution is advised in severe impairment. Desloratadine, an active metabolite of loratadine, is similarly hepatically metabolised and may be an alternative option.

• Fexofenadine undergoes minimal metabolism and is eliminated predominantly via the faeces rather than the kidneys. However, renal impairment can increase drug exposure, and the UK SmPC advises a starting dose of 60 mg once daily in patients with significant kidney impairment.

No single antihistamine is universally designated as the preferred choice in CKD by UK clinical guidelines. Selection should be individualised, based on the patient's eGFR, comorbidities, and current BNF or SmPC guidance. Patients should always confirm suitability with a GP or pharmacist before starting treatment.

Allergy Medications to Use With Caution or Avoid

Decongestants and NSAIDs should be avoided in significant renal impairment due to risks of raised blood pressure and acute kidney injury; intranasal corticosteroids and montelukast are generally safer options, though montelukast carries an MHRA warning for neuropsychiatric reactions.

Beyond antihistamines, several other allergy-related medications warrant particular caution in patients with kidney disease.

Decongestants such as pseudoephedrine and phenylephrine — found in many over-the-counter cold and allergy remedies — can raise blood pressure and reduce blood flow to the kidneys. UK SmPC guidance and NHS advice caution against their use in patients with uncontrolled hypertension, cardiovascular disease, or significant renal impairment. The MHRA has also issued safety communications regarding pseudoephedrine and the risk of serious cerebrovascular events. Patients with CKD should seek pharmacist or GP advice before using any product containing a decongestant.

Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen are sometimes used to manage allergy-related symptoms such as sinus pain. However, NSAIDs are well-established nephrotoxins — they reduce renal perfusion by inhibiting prostaglandin synthesis and can precipitate acute kidney injury, particularly in those with pre-existing CKD. The risk is substantially increased in patients who are also taking an ACE inhibitor or angiotensin receptor blocker (ARB) alongside a diuretic — a combination known as the 'triple whammy' — which is common in CKD management. The MHRA and NHS advise that NSAIDs should be avoided in patients with significant kidney impairment. Patients should discuss safer analgesic alternatives with their GP or pharmacist.

Intranasal corticosteroids (e.g., fluticasone, beclometasone) are considered safe for most patients with kidney disease, as systemic absorption is minimal and they are not renally excreted to a clinically significant degree. They are a preferred first-line option for managing allergic rhinitis in this population, in line with NHS and ARIA guidance.

Leukotriene receptor antagonists such as montelukast are hepatically metabolised and do not require dose adjustment in renal impairment, making them a reasonable option when antihistamines alone are insufficient. However, the MHRA has issued a Drug Safety Update highlighting the risk of neuropsychiatric reactions with montelukast — including sleep disturbances, mood changes, and suicidal thoughts. Patients and carers should be made aware of these risks before starting treatment and should seek prompt medical advice if such symptoms occur. Always check the current SmPC or seek pharmacist advice before initiating any new allergy treatment.

UK Guidance on Dosing With Reduced Kidney Function

The BNF and individual SmPCs provide authoritative UK dosing guidance for renal impairment; cetirizine requires dose reduction, fexofenadine should be started at 60 mg once daily, and suspected side effects should be reported via the MHRA Yellow Card scheme.

The British National Formulary (BNF) and individual drug SmPCs — available via the electronic Medicines Compendium (emc) — provide the authoritative UK guidance on dose adjustments for patients with renal impairment. These recommendations are based on the degree of kidney function, categorised by eGFR, and vary between products. The information below reflects general principles; always verify current dosing in the BNF or relevant SmPC before prescribing or recommending a medicine.

For cetirizine, the BNF and UK SmPC advise dose reduction in moderate-to-severe renal impairment (a dose of 5 mg once daily is commonly recommended when eGFR falls below a product-specific threshold, typically 30–50 mL/min/1.73m²). Cetirizine is generally not recommended or is contraindicated in end-stage renal disease — confirm the current recommendation in the relevant SmPC.

For loratadine, dose adjustment is not routinely required in mild-to-moderate renal impairment, though the BNF advises caution in severe impairment.

For fexofenadine, the UK SmPC advises a starting dose of 60 mg once daily in patients with significant renal impairment, reflecting increased drug exposure rather than a change in elimination route.

NICE guidance on CKD (NG203) emphasises the importance of reviewing all medications — including over-the-counter products — in patients with reduced kidney function. Patients are encouraged to inform their GP or pharmacist of all medications they are taking, including those purchased without a prescription.

If you experience a suspected side effect from any allergy medication, you can report it directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. This reporting system helps identify kidney-related and other adverse drug reactions and contributes to ongoing medicine safety monitoring in the UK.

Talking to Your GP or Pharmacist About Safe Allergy Treatment

Patients with CKD should inform their GP or pharmacist of their eGFR and full medication list before starting any allergy treatment, as many OTC remedies can interact with CKD medications or worsen kidney function.

Open communication with your GP or community pharmacist is essential when managing allergies alongside kidney disease. Many patients are unaware that over-the-counter allergy remedies can interact with kidney function or with other medications commonly prescribed for CKD, such as ACE inhibitors, ARBs, diuretics, or immunosuppressants.

Before starting any new allergy medication, it is advisable to:

• Inform your GP or pharmacist of your current eGFR and CKD stage

• Provide a full medication list, including supplements and herbal remedies

• Ask specifically whether the allergy medication requires dose adjustment in kidney disease

• Avoid OTC NSAIDs (such as ibuprofen) for pain relief without first discussing safer alternatives with your GP or pharmacist — particularly if you are already taking an ACE inhibitor, ARB, or diuretic

• Avoid assuming that 'natural' or herbal antihistamine alternatives are automatically safe — some, such as butterbur, have limited safety data in renal impairment

Your pharmacist can access the BNF and SmPC to check renal dosing guidance quickly and confidentially. If you experience any new or worsening symptoms after starting an allergy medication — such as reduced urine output, swelling, unusual fatigue, or a significant change in blood pressure — contact your GP promptly, as these may indicate an adverse renal effect.

If you or someone nearby develops signs of a severe allergic reaction (anaphylaxis) — including difficulty breathing, throat swelling, or sudden dizziness or collapse — call 999 immediately. Anaphylaxis is a medical emergency.

Patients with CKD who are under the care of a nephrologist should ideally have allergy treatment reviewed as part of their regular medication reconciliation, to ensure any new treatment is consistent with their overall kidney management plan.

Managing Allergies Safely Alongside Kidney Conditions

Effective allergy management in CKD combines non-pharmacological strategies with carefully selected medications; intranasal corticosteroids are first-line, antihistamine choice should be individualised by eGFR, and regular kidney function monitoring enables early detection of any deterioration.

Effective allergy management in patients with kidney disease is entirely achievable with the right approach. The goal is to control symptoms — whether allergic rhinitis, urticaria, or other allergic conditions — whilst minimising any additional burden on kidney function.

Non-pharmacological strategies should always be considered alongside or before medication:

• Identifying and avoiding known allergen triggers (e.g., pollen, dust mites, pet dander)

• Using saline nasal rinses to relieve nasal congestion without systemic drug exposure

• Keeping windows closed during high pollen seasons and monitoring pollen forecasts via the Met Office or NHS resources

When medication is necessary, intranasal corticosteroids remain a first-line option for allergic rhinitis due to their minimal systemic absorption and favourable safety profile in CKD, consistent with NHS and ARIA guidance. For eye symptoms, topical options such as sodium cromoglicate or olopatadine eye drops offer effective symptom relief with very low systemic exposure.

For oral antihistamines, selection should be individualised based on the patient's eGFR, comorbidities, and current BNF or SmPC guidance. Loratadine and desloratadine are hepatically metabolised options that do not typically require renal dose adjustment in mild-to-moderate CKD. Cetirizine and fexofenadine may also be used, but require dose adjustment in significant renal impairment as described in the relevant SmPC. Patients should use licensed doses and consult their GP or pharmacist before making any changes, particularly in the context of CKD.

For skin-related allergic conditions such as urticaria, topical treatments and oral antihistamines at appropriate licensed doses may be sufficient; however, dose escalation strategies sometimes used in urticaria management may not be suitable in CKD and should be discussed with a clinician.

Regular monitoring of kidney function (eGFR and urine albumin-to-creatinine ratio) as recommended by NICE NG203 allows clinicians to detect any deterioration early and adjust treatment accordingly. Patients should feel empowered to ask questions and advocate for a treatment plan that addresses both their allergy symptoms and their kidney health. With careful medication selection, appropriate dosing, and regular review, most people with CKD can manage their allergies safely and effectively.

To report a suspected side effect from any allergy medication, use the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions